Related Experiment Video
Updated: Sep 7, 2025
Human Dupuytren's Ex Vivo Culture for the Study of Myofibroblasts and Extracellular Matrix Interactions
Published on: April 18, 2015
Patient Insight With Collagenase Treatment for Dupuytren: A Prospective Study
Rafael Sanjuan-Cervero1, Diego Gomez-Herrero2, Fernando Peña-Molina1
1Orthopedics and Trauma Department, Hospital de Denia, Denia, Alicante, Spain.
Purpose:
There appears to be controversy regarding differing patient and physician perceptions of adverse effects (AEs) in the treatment of Dupuytren disease with collagenase clostridium histolyticum (CCH). The aim of this study was to compare the number, type, and severity of AEs perceived and reported by patients and by their physician METHODS: To assess AEs following CCH injection in a standardized way, patients were given a list of predefined complications and asked to rate their severity on a 4-point Likert scale ranging from 1 (serious) to 4 (insignificant).
Results:
Eighty-five patients were included. Patients reported fewer AEs than their physician (mean, 1.48 vs 2.18). There was no agreement between physician- and patient-reported AEs except for skin lacerations, which showed fair agreement (κ = 0.257).
Conclusions:
Patients and physicians differ in their evaluation of AEs due to CCH treatment in Dupuytren disease. A fair level of agreement was observed for skin lacerations.
Clinical Relevance:
Greater consensus is needed when defining AEs associated with CCH in the treatment of Dupuytren disease.
